RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro™ lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.